Cooperative Agreement U01CA291666
Award Date
9/13/24
Completion Date
8/31/29
Dollars Obligated
$957K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute awarded a $317,420 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Calla Health Foundation, a for-profit, woman-owned small business, for the development and validation of a patient-ready device called the CallaScope. This innovative technology aims to transform provider-controlled speculum-based imaging in a clinic to a patient-controlled self-imaging procedure at home, enabling increased access to cervical cancer screening, diagnosis,...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
The National Cancer Institute awarded a $1,456,920 Cooperative Agreement (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Vanderbilt University Medical Center to develop and validate a point-of-care breast cancer diagnostic kit for use in primary care clinics in Uganda. The proposed kit combines an automated AI-enabled whole breast ultrasound and a smartphone-based AI-powered device that performs cytology imaging and quantifies tumor biomarkers. The project will validate the kit's...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop their digital pathology "laboratory-in-a-box" solution that rapidly produces and analyzes high-resolution, 3D digital pathology images for skin cancer detection at the point of care. The specific goals are to: 1) refine the AI algorithms for improved detection of basal and squamous cell carcinomas, 2) develop...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Argosmd, Inc. to develop a low-cost, non-invasive "Mini-Reflectance Confocal Microscope (Mini-RCM)" device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging microscopy tool that can improve upon existing Reflectance Confocal Microscopy (RCM) technology, which is currently limited in adoption due to...
This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $440,287 to GE Medical Systems Information Technologies, Inc. to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize biobanking for low-resource institutes by enabling molecular analysis from smaller tumor samples, including those less than 10,000...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...